$938 Million deal on FGF21/GLP-1 bispecific fusion protein! Are you looking for a similar product? We can help!

2024年11月12日 22:20 • Product for Licensing • 阅读 121

If you are looking for similar products, please feel free to contact DrugTimes BD Team. We can help you find quality products and partners quickly

On November 12th, Apollo Therapeutics announced that it has entered into an exclusive licensing agreement with Sunshine Lake Pharmaceutical for the development of APL-18881 (HEC88473). APL-18881 is a bispecific fusion protein targeting the FGF21 receptor and the GLP-1 receptor, developed by Sunshine Lake Pharma. The total value of the deal is $938 million.

Apollo Therapeutics Signs Exclusive Ex-China License From Sunshine Lake Pharma for Clinical-Stage FGF21 / GLP-1 Dual Receptor Agonist, a Therapeutic With Major Commercial Potential in Multiple Indications

If you are looking for similar products, please feel free to contact DrugTimes BD Team. We can help you find quality products and partners quickly.

Please contact us at BD@drugtimes.cn.

Thank you very much!

发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权